OneOncology Appoints Two New Board Members While Clinical Research as Care Option Thrives

OneOncology Appoints Two New Board Members While Clinical Research as Care Option Thrives

OneOncology, the private equity-backed national platform for independent community oncology practices, announced two new Board of Managers and shared with TrialSite the robust clinical trials activity conducted at community oncology practices around the United States. With a $200 million capital infusion to propel the expansion of this important community-centric oncology practice model in 2018, OneOncology shared with TrialSite recently that the network of community cancer practices now participates in 580 clinical trials with 2,102 patients enrolled, as reported in their 2020 annual report. The network of community cancer practices now supports nearly a quarter million cancer patients across seven states. These numbers will continue to go up as the organization expands and executes on its important mission of achieving both network scale while emphasizing the local community practice. Importantly, the organization will become more influential in research, contributing to a growing number of clinical trials. To help with the ongoing execution, the organization expanded its board level management to include Natalie Dickson, MD, President and Chief Medical Officer for Tennessee Oncology, and Curtis Warfield, President and Chief Executive Officer of Windham Advisor, a private equity and strategic advisory firm. Mr. Warfield will also chair OneOncology’s Audit and Compliance Committees.

Thriving even During Pandemic

2020 was a tough year, but OneOncology continues to successfully execute its growth strategy involving both community-level cancer care and expansion of a vast, national network that supports nationwide clinical trials, from coast to coast.

A review of the network’s 2020 Annual Report indicates that in 2020 the network treated a total of 247,252 cancer patients across their community settings. The breakdown of patient by type of cancer includes the following:

·         Breast Cancers, 43,080

·         Hematologic Cancers, 32,983

·         Prostate and Male GU Cancers, 9,838

·         Colorectal Cancers,9,472

·         Lung Cancers, 9,469

·         Gynecologic Cancers, 6,075

·         Upper Gastrointestinal & Hepatobiliary Cancers, 5,041

·         Kidney, Bladder and other Urinary Cancers, 3,856

·         Melanoma & other Skin Cancers, 3,745

·         Head & Neck Cancers, 3,377

·         Brain & Nervous System Cancers, 782

·         Other Cancers, 5,651

OneOncology’s clinical trials group has taken off now conducting 580 open cancer trials across the country across a range of cancers with 2, 102 patients enrolled to date.

Board Manager Additions

As the national platform reported recently in a press release Dr. Natalie Dickson and Curtis Warfield each bring significant experience that will enhance our Board,” said David Chernow, Chairman of OneOncology’s Board of Managers. “Dr. Dickson is an incredible physician leader, and Curtis Warfield has a wealth of board, technology and payer experience in healthcare. I’m looking forward to working with both of them to enhance the delivery of cancer care and benefit the practice partners we serve.”    

Dr. Dickson is President and Chief Medical Officer for Tennessee Oncology, where she guides process improvement, regulatory affairs and safety initiatives. She is also skilled in stakeholder management, maintaining a cooperative working relationship along the healthcare continuum with staff, physicians, hospitals and payers. Her passion for improving the delivery of care for patients drives her focus on physician-led collaboration with technology vendors, pharmaceutical innovators and other organizations. As Tennessee Oncology leads in the implementation of alternative payment models, Dr. Dickson is focused on prioritizing quality initiatives, reducing unnecessary variation, and analyzing and sharing performance metrics. Dr. Dickson also has maintained an active hematology-oncology practice for the past 22 years.

Curtis Warfield, an accomplished C-suite executive, has served in senior roles with three Fortune 500 companies. In addition to his leadership role at Windham Advisors, he is also currently a board member of Texas Roadhouse, a publicly traded global brand, as well as the Chairman of its Nominating and Governance Committee.

Mr. Warfield, who is a U.S. Securities and Exchange Commission expert and a certified public accountant, has also served as part of the senior leadership team of Anthem, Inc., one of the nation’s largest health insurers with over $100 billion in revenues, from 2017 to 2019.  As a senior executive at HCA, the largest healthcare provider in the country, from 1997 to 2016 he held a variety of roles with the majority of his tenure as the Chief Executive Officer of NPAS, a healthcare services company.

With these additions, OneOncology’s nine-member Board of Managers consists of five physicians. Board members are Jeff Patton, MD, CEO; David Chernow, Chairman; Natalie Dickson, MD; Senator Bill Frist, MD; Edward Licitra, MD; Justin Sunshine; Jeff Vacirca, MD; Robbert Vorhoff; and Curtis Warfield.

About OneOncology

OneOncology is the national platform for independent community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven and patient-centric model. OneOncology comprises leading community oncology practices representing more than 550 providers practicing at more than 175 sites of care across the United States. Those interested in learning more can visit the organization’s website.

Call to Action: Interested in connecting with OneOncology? Check in with Eric Hoffman at 202.285.0810 or email at [email protected]

Responses